Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.42 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | HTR2B | P41595 | 3/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29613747 | 1.00 | HTR2C (0.42) | HTR2CHTR2AHTR2BCHRNB2CHRNA4 | |
| SCHEMBL7376647 | 0.86 | HTR2C (0.42) | HTR2CHTR2AHTR2BCHRNB2CHRNA4 | |
| SCHEMBL10724594 | 0.84 | HTR2A (0.49) | HTR2CHTR2AHTR2BTAAR1SIGMAR1 | |
| SCHEMBL9278829 | 0.83 | HTR2C (0.59) | HTR2CHTR2AHTR2BCHRNB2CHRNA4 | |
| SCHEMBL1897659 | 0.83 | HTR2C (0.59) | HTR2CHTR2AHTR2BCHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL9672275 | 0.81 | HTR2C (0.57) | HTR2CHTR2AHTR2BCHRNB2CHRNA4 | |
| SCHEMBL3886540 | 0.77 | ADRA2A (0.39) | HTR2CHTR2AHTR2BSIGMAR1 | |
| SCHEMBL7109787 | 0.77 | HTR2C (0.45) | HTR2CHTR2AHTR2B | |
| SCHEMBL448237 | 0.77 | CHRNB2 (0.39) | HTR2CHTR2ACHRNB2CHRNA4 | |
| SCHEMBL352937 | 0.77 | SIGMAR1 (0.47) | HTR2CHTR2AHTR2BHRH3KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428423-B2 | 1H-imidazo[4,5-h]quinazoline compound as protein kinase inhibitor | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2025-09-30 | — | — | US | disclosed |
| US-20250026719-A1 | NOVEL COMPOUNDS AS INHIBITORS OF PCSK9 | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2025-01-23 | — | — | US | disclosed |
| US-11993604-B2 | Substituted pyrazolo[4,3-H]quinazolines as protein kinase inhibitors | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2024-05-28 | — | — | US | disclosed |
| US-20230312583-A1 | 1H-IMIDAZO [4,5-H] QUINAZOLINE COMPOUND AS NOVEL SELECTIVE FLT3 INHIBITORS | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230122967-A1 | NOVEL COMPOUNDS AS INHIBITORS OF PCSK9 | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| US-20220315584-A1 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2022-10-06 | — | — | US | disclosed |
| EP-3608321-B1 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | SHENGKE PHARMACEUTICALS JIANGSU LTD (CN) | 2022-09-07 | — | — | EP | disclosed |
| US-20220227775-A1 | 1H-PYRAZOLO[4,3-H]QUINAZOLINE COMPOUND SERVING AS PROTEIN KINASE INHIBITOR | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2022-07-21 | — | — | US | disclosed |
| CN-111094291-B | 1H-pyrazolo [4,3-H ] quinazoline compound as protein kinase inhibitor | 晟科药业（江苏）有限公司 | 2022-06-21 | — | — | CN | disclosed |
| EP-3666774-B1 | 1H-PYRAZOLO[4,3-H]QUINAZOLINE COMPOUND SERVING AS PROTEIN KINASE INHIBITOR | SHENGKE PHARMACEUTICALS JIANGSU LTD (CN) | 2022-05-11 | — | — | EP | disclosed |
| US-20110060003-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | UNIVERSITY OF KANSAS | 2011-03-10 | — | — | US | disclosed |
| WO-2011005759-A2 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | UNIVERSITY OF KANSAS (US) | 2011-01-13 | — | — | WO | disclosed |
| US-20090238760-A1 | ANTISPERMATOGENIC, SPERMICIDAL AND/OR ANTIFUNGAL COMPOSITION AND METHODS OF USING THE SAME | RESEARCH TRIANGLE INSTITUTE (US) | 2009-09-24 | — | — | US | disclosed |
| EP-1506779-B1 | (3-(4-(Pyridin-2-ylamino)-butyryl)-2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluoren-9-yl)-acetic acid derivatives and related tricyclic indanyls as alphaVbeta3 and alphaVbeta5 integrin inhibitors for the treatment of cancer and unstable angina | JANSSEN PHARMACEUTICA NV (BE) | 2006-07-12 | — | — | EP | disclosed |
| EP-1506779-A1 | (3-(4-(Pyridin-2-ylamino)-butyryl)-2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluoren-9-yl)-acetic acid derivatives and related tricyclic indanyls as alphaVbeta3 and alphaVbeta5 integrin inhibitors for the treatment of cancer and unstable angina | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | disclosed |
| EP-0505510-A1 | ANTIPSYCHOTIC HEXAHYDRO-2$i(H)-INDENO 1,2-c]PYRIDINE DERIVATIVES | MCNEILAB, INC. (US) | 1992-09-30 | — | — | EP | disclosed |
| US-5075315-A | Dopamine, serotonin antagonists | MCNEILAB, INC. (US) | 1991-12-24 | — | — | US | disclosed |
| US-5075315-A | Dopamine, serotonin antagonists | MCNEILAB, INC. (US) | 1991-12-24 | — | — | US | disclosed |
| US-5075315-A | Dopamine, serotonin antagonists | MCNEILAB, INC. (US) | 1991-12-24 | — | — | US | disclosed |
| WO-1991017992-A1 | ANTIPSYCHOTIC HEXAHYDRO-2H-INDENO[1,2-c]PYRIDINE DERIVATIVES | MCNEILAB INC. (US) | 1991-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315584-A1 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | CDK4, CDK2, CDKL1 | HTR2C 1838/4885HTR2A 3135/4885HTR2B 3308/4885 |
| US-20230312583-A1 | 1H-IMIDAZO [4,5-H] QUINAZOLINE COMPOUND AS NOVEL SELECTIVE FLT3 INHIBITORS | FLT3, ABL1, FLI1 | HTR2C 2423/4885HTR2A 3990/4885HTR2B 3385/4885 |
| US-11993604-B2 | Substituted pyrazolo[4,3-H]quinazolines as protein kinase inhibitors | CDK1, CDK2, CDK3 | HTR2C 1782/4885HTR2A 3511/4885HTR2B 3257/4885 |
| US-20220227775-A1 | 1H-PYRAZOLO[4,3-H]QUINAZOLINE COMPOUND SERVING AS PROTEIN KINASE INHIBITOR | CDK1, CDKL1, CDK2 | HTR2C 1707/4885HTR2A 3204/4885HTR2B 3020/4885 |
| US-20250026719-A1 | NOVEL COMPOUNDS AS INHIBITORS OF PCSK9 | PCSK9, PCSK7, PCSK6 | HTR2C 4204/4885HTR2A 4174/4885HTR2B 3697/4885 |
| US-20230122967-A1 | NOVEL COMPOUNDS AS INHIBITORS OF PCSK9 | PCSK9, PCSK7, PCSK6 | HTR2C 4204/4885HTR2A 4174/4885HTR2B 3697/4885 |
| US-12428423-B2 | 1H-imidazo[4,5-h]quinazoline compound as protein kinase inhibitor | CDK4, CDK2, CDKL1 | HTR2C 1838/4885HTR2A 3135/4885HTR2B 3308/4885 |
| US-20090238760-A1 | ANTISPERMATOGENIC, SPERMICIDAL AND/OR ANTIFUNGAL COMPOSITION AND METHODS OF USING THE SAME | NASP, CATSPER1, ACR | HTR2C 2942/4885HTR2A 2877/4885HTR2B 1532/4885 |
| US-20110060003-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | SHBG, GNRHR, FSHR | HTR2C 2071/4885HTR2A 730/4885HTR2B 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.